Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Suspended 1

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Lymphoma 2Waldenstrom Macroglobulinemia 1Pancreatic Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 62Vincristine 45Doxorubicin 43Etoposide 42Rituximab 37Prednisone 31Filgrastim 31Biopsy 27Peripheral Blood Stem Cell Transplantation 25Cytarabine 24Radiotherapy 22fludarabine phosphate 19Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 18Prednisolone 17Melphalan 16Ifosfamide 14Dexamethasone 14Bleomycin 13Leucovorin 12Cyclosporine 12Carmustine 12sargramostim 11Cisplatin 10Vinblastine 8Chlorambucil 8Busulfan 8fludarabine 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lymphoma × Antibodies, Monoclonal × Clear all
NCT00324831 2013-12-18

GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

National Cancer Institute (NCI)

Phase 3 Suspended
480 enrolled
Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT00265928 2008-01-28

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
46 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡